A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors
Eine Real-World-Datenanalyse zum Einfluss von klonaler Hämatopoese mit unbestimmtem Potenzial auf Wirksamkeit und Nebenwirkungen von Immun-Checkpoint-Inhibitoren
Cancer · 01.06.2026 · 132 (11)
DOI: 10.1002/cncr.70398 ↗Auf einen Blick
Bei 2.040 Patient:innen mit fortgeschrittenen soliden Tumoren war CHIP mit einer längeren Behandlungsdauer unter ICI verbunden. Ein Zusammenhang mit schweren irAE zeigte sich nicht.
Fragestellung
Beeinflusst CHIP die Wirksamkeit und Sicherheit von Immun-Checkpoint-Inhibitoren bei fortgeschrittenen soliden Tumoren?
Methode
Retrospektive Analyse von Real-World-Daten aus 2.040 Patient:innen mit fortgeschrittenen soliden Tumoren und ICI-Therapie; CHIP per Liquid Biopsy und Genpanel untersucht.
Ergebnisse
CHIP lag bei 25,7 % vor. CHIP-positiv: längere TTD 10,1 vs. 7,9 Monate; HR 0,81; p=.005. TET2: 10,3 vs. 8,2 Monate; HR 0,77; p=.035. Keine signifikante Assoziation mit grade ≥3 irAE.
Schlussfolgerung der Autor:innen
In dieser Real-World-Kohorte war CHIP, besonders TET2, mit einer längeren Dauer der ICI-Behandlung assoziiert. CHIP könnte ein Biomarker für den klinischen Nutzen von ICIs sein.
Kernaussagen
- CHIP bei 25,7 % der Fälle nachweisbar
- Längere TTD bei CHIP-positiven Patient:innen
- Keine signifikante Assoziation mit grade ≥3 irAE
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 29.05.2026. Verfasst von Takamasa Fujita und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Cancer Medicine, Institute of Science Tokyo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Immune Checkpoint Inhibitors, Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Clonal hematopoiesis of indeterminate potential (CHIP) has been implicated in systemic inflammation. Although immune checkpoint inhibitors (ICIs) have transformed cancer care, their response rates remain modest, and some patients experience severe immune‐related adverse events (irAEs). This study investigated whether CHIP affects ICI treatment efficacy and safety in patients with advanced solid tumors.
Methods
Data from 2040 individuals with advanced solid tumors who underwent liquid biopsy–based gene panel testing and received ICI therapy (with or without chemotherapy) were retrospectively analyzed. CHIP was defined as the presence of mutations in DNMT3A , TET2 , or ASXL1 at a variant allele frequency ≥0.02. Overall response rate (ORR), disease control rate (DCR), real‐world time to discontinuation (TTD), and the incidence of grade ≥3 irAEs were compared between CHIP‐positive and CHIP‐negative groups.
Results
CHIP was detected in 25.7% of cases. CHIP‐positive group exhibited significantly prolonged TTD (median, 10.1 vs. 7.9 months; hazard ratio, 0.81; p = .005). Gene‐specific analyses showed that TET2 was independently associated with longer TTD (median, 10.3 vs. 8.2 months; hazard ratio, 0.77; p = .035), whereas DNMT3A displayed a similar but nonsignificant trend. In contrast, ASXL1 ‐positive patients had a lower ORR yet still showed a trend toward longer TTD. No significant association was observed between CHIP and the incidence of grade ≥3 irAEs.
Conclusion
In this real‐world cohort, CHIP, particularly TET2 mutations, was associated with prolonged ICI treatment duration. These findings suggest that CHIP may serve as a potential biomarker for predicting the clinical benefit of ICIs in advanced solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Cancer Medicine, Institute of Science Tokyo Hospital, Tokyo, Japan.
- Department of Gastrointestinal Surgery, Institute of Science Tokyo, Tokyo, Japan.
- Department of Bioresource Research Support Center, Institute of Science Tokyo, Tokyo, Japan.
- Department of AI Technology Development, M&D Data Science Center, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Takamasa Fujita
Zitieren
APA
Fujita, T., Ishibashi, N., Aoyama, S., Kobayashi, Y., Kamatani, T., Kinugasa, Y., & Ikeda, S. (2026). A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors. Cancer, 132(11). https://doi.org/10.1002/cncr.70398
Vancouver
Fujita T, Ishibashi N, Aoyama S, Kobayashi Y, Kamatani T, Kinugasa Y, et al. A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors. Cancer. 2026;132(11). doi:10.1002/cncr.70398
BibTeX
@article{Fujita2026,
author = {Fujita, Takamasa and Ishibashi, Naoya and Aoyama, Satoru and Kobayashi, Yumi and Kamatani, Takashi and Kinugasa, Yusuke and Ikeda, Sadakatsu},
title = {A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors},
journal = {Cancer},
year = {2026},
volume = {132},
number = {11},
doi = {10.1002/cncr.70398}
}
EUVIMED